Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasms Clear all
Active, not recruiting Phase 1 Interventional

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

NCT03332797
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-9545, Palbociclib, LHRH Agonist
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 8:27 AM EDT
Completed No phase listed Observational

Automated Pain Intervention for Underserved Minority Breast Cancer Patients

NCT00881010
View directory record Official record
Conditions
Breast Cancer
Interventions
Telephone Intervention, Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 23, 2026, 8:27 AM EDT
Terminated Phase 2 Interventional Results available

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

NCT04383210
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 23, 2026, 8:27 AM EDT
Recruiting Phase 2 Interventional

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

NCT05020860
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Interventions
Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Pembrolizumab, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 23, 2026, 8:27 AM EDT
Completed No phase listed Observational

Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis

NCT00264082
View directory record Official record
Conditions
Breast Cancer
Interventions
Zometa(drug)
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Intellectual Impairment in Women With Breast Cancer

NCT00896324
View directory record Official record
Conditions
Breast Cancer
Interventions
Cognitive Rehabilitation, Active Neurofeedback Training, Neurofeedback Training (placebo / Sham)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 23, 2026, 8:27 AM EDT
Terminated Phase 2 Interventional

High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

NCT00131924
View directory record Official record
Conditions
Breast Cancer
Interventions
esterified estrogens
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

NCT00194779
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, paclitaxel, filgrastim, capecitabine, methotrexate, vinorelbine tartrate, needle biopsy, therapeutic conventional surgery, immunohistochemistry staining method, trastuzumab, tamoxifen citrate, letrozole, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

Multi-Media Imagery Program for Breast Cancer Patients (Phase II)

NCT01034215
View directory record Official record
Conditions
Breast Cancer
Interventions
Envision the Rhythms of Life Program, Envision the Rhythms of Life Program/Distance
Behavioral
Lead sponsor
Mind Matters Research LLC
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 23, 2026, 8:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

NCT00291096
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Carol Fabian, MD
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer

NCT01892540
View directory record Official record
Conditions
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
positron emission tomography/computed tomography, PET/MRI, Position Device
Diagnostic Test · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 23, 2026, 8:27 AM EDT
Active, not recruiting No phase listed Observational

Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)

NCT03927768
View directory record Official record
Conditions
Breast Cancer
Interventions
Predictive Model, Breast Imagers
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 8:27 AM EDT
Recruiting Early Phase 1 Interventional

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT05464810
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Letrozole, Simvastatin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

NCT00010010
View directory record Official record
Conditions
Breast Cancer
Interventions
exemestane, goserelin acetate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer

NCT03018080
View directory record Official record
Conditions
Breast - Female, Male Breast Cancer
Interventions
Pembrolizumab, Paclitaxel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 23, 2026, 8:27 AM EDT
Not yet recruiting Phase 2 Interventional

De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer

NCT07866430
View directory record Official record
Conditions
Brest Cancer ER+ and HER2 Negative
Interventions
Letrozole
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 8:27 AM EDT
Recruiting Phase 1 Interventional

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

NCT07137871
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Avasopasem
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 23, 2026, 8:27 AM EDT
Terminated Early Phase 1 Interventional

MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors

NCT06274034
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Electronic Health Record Review, Medical Device Usage and Evaluation, Meditation Therapy, Survey Administration
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Postoperative Opt-In Narcotics Treatment in Breast

NCT05078398
View directory record Official record
Conditions
Breast Cancer, Breast Surgery, Opioid Use
Interventions
POINT Protocol, Usual care
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 23, 2026, 8:27 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

NCT02204098
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions
Mammaglobin-A DNA Vaccine, Optional biopsy
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner

NCT02597452
View directory record Official record
Conditions
Breast Cancer
Interventions
intelligent Breast Exam, iBE
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors

NCT02763228
View directory record Official record
Conditions
Breast Cancer, Physical Activity
Interventions
Aerobic Training - Fixed Schedule, Resistance Training - Fixed Schedule, Walking program, Aerobic Training - Flexible Schedule, Resistance Training - Flexible Schedule, Successful Survivorship Health Education and Support Group, Flexible support groups
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 23, 2026, 8:27 AM EDT
Completed Phase 3 Interventional

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

NCT00003600
View directory record Official record
Conditions
Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, placebo
Biological · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
20
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 23, 2026, 8:27 AM EDT